1-8 of 8
Russell J. Schilder
Close
Sort by
Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2753.
https://doi.org/10.1182/blood.V120.21.2753.2753
Published: 2012
Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell R. Smith, MD, Ph.D., Michael Millenson, MD, Linda Thibodeau, RN, Nicole Kamiensky, Russell J. Schilder, MD
Journal: Blood
Blood (2007) 110 (11): 4485.
https://doi.org/10.1182/blood.V110.11.4485.4485
Published: 2007
Journal Articles

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Danielle Shafer, DO, Hossein Borghaei, DO, Michael Millenson, MD, Nicos Nicolaou, MD, Tahseen I. Al-Saleem, MD, Nick C. Leasure, MD, Kris Padavic, RN, Mitchell R. Smith, MD, PhD, Russell J. Schilder, MD
Journal: Blood
Blood (2005) 106 (11): 2677.
https://doi.org/10.1182/blood.V106.11.2677.2677
Published: 2005
Journal Articles

Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).

Russell J. Schilder, MD, Thomas E. Witzig, MD, Ian Flinn, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Hua Wang, MS, Katie Vo, Arturo Molina, MD.
Journal: Blood
Blood (2004) 104 (11): 2629.
https://doi.org/10.1182/blood.V104.11.2629.2629
Published: 2004
Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD
Journal: Blood
Blood (2004) 104 (11): 2634.
https://doi.org/10.1182/blood.V104.11.2634.2634
Published: 2004
Journal Articles

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Clinical Trials & Observations Brief Report
Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White
Journal: Blood
Blood (2004) 103 (12): 4429–4431.
https://doi.org/10.1182/blood-2003-11-3883
Published: 2004
Journal Articles

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Clinical Trials & Observations
Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor Saleh, Roberta S. Allen, Antonio J. Grillo-López, Christine A. White
Journal: Blood
Blood (2002) 99 (12): 4336–4342.
https://doi.org/10.1182/blood.V99.12.4336
Published: 2002
Journal Articles

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, Brian K. Dallaire, Ken Wey, Ivor Royston, Thomas Davis, Ronald Levy
Journal: Blood
Blood (1997) 90 (6): 2188–2195.
https://doi.org/10.1182/blood.V90.6.2188
Published: 1997